Patient with wrinkle at cheek and periorbital with score of -2 to -1 by wrinkle patient assessment score Facial Rejuvenation, Autologous Fibroblasts, wrinkle at cheek and periorbital
Conditions
Interventions
Patients were treated by first punch biopsy at back of the ear which inject adrenaline before biopsy. Second the biopsy will be cultured at sterile standard room. Then the patient will be injected by
Experimental Device
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 older 2. Patient with wrinkle at cheek and periorbital with score of -2 to -1 by wrinkle patient assessment score which have 5 score : Very satisfied(+2), Satisfied(+1), Mild satisfied(0), not satisfied(-1), very not satified(-2)
Exclusion criteria
Exclusion criteria: 1. Patients who are pregnant, lactating, and postpartum. 2.Patient with autoimmune disease, transplantation, cancer, fibroblast or collagen genetic disorder for example Epidermolysis bullosa, Ataxia telangiectasis, skin cancer or others disease that affect the research. 3.Patient with history of treatment by autologous fibroblast . 4.Patient with history of treatment by inject any substances at cheek or lower face in 12 months before the research. 5.Patient with history of treatment by focus ultrasound or ablative laser or others that affect the cheek or lower face in 12 months before the research. 6.Patient with history of treatment by ultra phono, chemical peeling and cream or drug for treat wrinkle like tretinoin at cheek or lower face within 1 month. 7.Allergy to collagen , diary products, Gentamicin A, Amphotericin B and local anesthesia. 8.Patient with bleeding precaution, thrombocytopenia, take an anti-platelet drug that cannot stop and taking steroid drug or immunosuppressive drug. 9.Patient with history of hypertrophic scar or Keloid .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin Wrinkle Baseline,1,3,6,12 months Antera,Skin Volume Baseline,1,3,6,12 months Vectra | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent improvement Baseline,1,3,6,12 months Dermatologist improvement scale,Percent improvement Baseline,1,3,6,12 months Patient improvement scale,Safety Baseline, After treatment, 1,3,6,12 months Adverse effect | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed